Summary The present study was designed to examine the feasibility of in vivo administration of interleukin 2 (IL-2) to induce cytotoxic cell activity against tumours in human subjects. IL-2 was prepared from blood leukocytes stimulated with phytohaemagglutinin (PHA) and partially purified by membrane chromatography to exclude PHA. Administration of different amounts of IL-2 in vivo to 2 patients with melanoma revealed that the initial level of IL-2 in the circulation was related to the dose given and had a half-life of -22.5 minutes. The initial and subsequent levels of IL-2 were lower than that expected to occur from equilibration in plasma and extracellular fluid. This was not apparently due to inactivation by serum factors because fresh human serum had little effect in vitro on the induction of mitogenic or cytotoxic activity by IL-2. Spontaneous division of lymphocytes was increased following IL-2 administration and it is suggested that clearance of IL-2 in vivo may reflect, in part, absorption by activated lymphocytes in the circulation. Side effects noted shortly after administration of the partially-purified IL-2 preparations included transient pyrexia, hypoglycaemia, increased cortisol levels, lymphocytopenia and signs of mild intravascular coagulation. No long-term effects were noted. These initial results suggest that systemic injection of purified preparations of II-2 may be a feasible approach to induce cytotoxic T cells in vivo.
Previous studies have shown that the lymphokine, interleukin 2 (IL-2), appears necessary as a second signal for the generation of cytotoxic T cells (Lafferty et al., 1980; Wagner et al., 1980a) . Addition of IL-2 from mitogen-stimulated lymphocytes to cultures of lymphocytes and tumour cells was shown to induce cytotoxic activity against syngeneic animal tumours (Mills & Paetkau, 1980; Warren et al., 1978 Warren et al., , 1979 Gillis & Watson, 1981) and against autologous human malignancies such as leukaemia (Zarling & Bach, 1979) , melanoma (Lotze et al., 1980) and various carcinomas (Vose & Bonnard, 1982; Vose & Moore, 1981) .
We have recently substantiated these studies by showing that culture of lymphocytes from patients with melanoma in IL-2 containing supernatants resulted in the induction of cytotoxic cells in vitro against autologous melanoma cells and a variety of allogeneic target cells (Hersey et al., 1981) . Culture of the lymphocytes with tumour cells was not necessary for the induction of cytotoxicity against the autologous melanoma cells. Similar findings were reported against autologous leukaemia cells and various carcinomas (Zarling & Bach, 1979; Vose & Moore, 1981) . IL-2 was shown previously to act on activated T cells rather than resting T cells (Lafferty et al., 1980) so that these results suggested T cells activated against melanoma antigens were present in the circulation of patients with melanoma.
In view of these findings it seemed possible that injection of IL-2 in vivo may lead to the induction of cytotoxic T cells against melanoma in patients analogous to the induction of cytotoxic T cells against allografts in nude mice by systemic administration of IL-2 (Wagner et al., 1980b) . With this in mind the present study was carried out to determine whether IL-2 could be detected in vivo after systemic injection in human subjects, and if so, to estimate the rate of clearance of IL-2 activity from the circulation. The results indicate that IL-2 can be detected by biological assays in the circulation for -I h after intravenous injection. The side effects noted were relatively mild and may be further reduced by administration of more purified preparations of IL-2.
Materials and methods

Patienits
These were 2 subjects with advanced melanoma.
(j The Macmillan Press Ltd., 1983 Patient I was a 26-year old male who presented with extensive pulmonary and pleural metastases 41 years after the removal of occular melanoma. He failed to respond to treatment with several courses of DTIC (Dacarbazine) (Flow Laboratories) culture medium (without foetal calf serum) for 24-36h. Further details of the procedures are described elsewhere (Hersey et al., 1981) . After membrane chromatography on YM30 membranes (Amicon) in 300-ml capacity Amicon diaflo cells to remove PHA, the volume of the supernatant was reduced to 60-100ml by ultrafiltration on YM5 (Amicon) membranes. This procedure was shown previously to remove PHA from the preparations as determined in mitogenic assays. Each batch was filtered through Millipore 0.45 um diameter filters and sterility checked by culture for bacteria and fungi. Assays for IL-2 activity, levels of interferon (IFN) and endotoxin were conducted on each batch.
IL-2 assays
Assays of IL-2 in supernatants were carried out as previously described (Hersey et al., 1981) . Normal blood lymphocytes which had been maintained in IL-2 for 7 days after stimulation by PHA for 3 days were used as the target cell populations. (TCA) and counted in a gamma counter. 125IUDR incorporation data were plotted against log2 of IL-2 dilution to give a dose-response curve. The x-axis dilution co-ordinate of the control sample which crossed this curve at the 50% maximum 125IUDR uptake (y-axis co-ordinate) was defined as that value which corresponded to 1 unit of IL-2 activity. Aliquots of the control sample of IL-2 were repeatedly used to standardize the activity of individual batches.
Assay of IL-2 activity in sera from the patients was carried out as follows: The assay cells as above were washed free of IL-2 and resuspended in RPMI 1640 + 10% FCS at 7.1 x 105/ml. 105 cells in 140 pl were placed in triplicate 70 x 1Omm roundbottomed tubes followed by 60 p1 of the serum sample to be assayed. (Final serum concentration 30%). Cultures were incubated for 24 h in a humidified atmosphere of 7% CO2 in air at 37°C with the addition of 2,pCi of radiolabelled iododeoxyuridine 125IUDR (New England Nuclear, Boston, Mass.) for the final 4h of culture. Cells were harvested by washing 3 x in saline and once in 5% trichloroacetic acid (TCA) and counts per minute (c.p.m.) measured in a y counter.
Six control human sera were used to give a baseline of cell turnover in the absence of IL-2 but in the presence of 30% human serum. Units/ml (uml-1) of IL-2 activity in serum were measured from a standard curve prepared by addition of 40pl of different dilutions of the infused IL-2 in RPMI to 60p1 of the patient's undiluted serum obtained (Hersey et al., 1982 
Cytotoxic assays
The 5"Cr release assays and target cells used in studies on the effect of fresh serum on IL-2 induced cytotoxic activity are fully described elsewhere (Hersey et al., 1981) .
Results
Effect of PHA and IL-2 on unstimulated blood mononuclear cells and IL-2 dependent cells
As shown in Table I , 1% PHA had little stimulating activity on the IL-2 dependent cells used in the assay. The table also shows that attempts to remove PHA from the crude IL-2 preparations by filtration through YM30 membranes and then concentration on YM5 membranes was effective in removing mitogenic activity for normal unstimulated blood lymphocytes.
IL-2 assays
Assay of the IL-2 activity in the partially purified supernatants given to the patients is shown in Figure 1 . An IL-2 preparation prepared from spleen cells from a patient with melanoma PAGE-SDS analysis of the IL-2 containing supernatants prepared by membrane chromatography as described revealed fractions with molecular weights (mol. wts.) of -10, [13] [14] [15] [16] 18, 20, 22, 24, 28, 32 and 67 Kilodaltons (Kd) . The predominant fraction was that detected at 13-16 Kd which from previous studies was likely to contain IL-2 (Mier & Gallo, 1980) . The 28 Kd fraction may have been a contaminant of PHA in that when the same amount of PHA as used for IL-2 production was processed as for IL-2 production and analysed by PAGE-SDS, a 28 Kd fraction was detected. (Before membrane chromatography the major fraction in the PHA had a mol. wt. of -32 Kd. Minor fractions were detected with mol. wts. of 28 and 12 Kd). The 67 Kd fraction in the IL-2 preparations may have been human serum albumin non-specifically absorbed to the human lymphocytes used for IL-2 preparation. (FCS was not added to the leukocytes during preparation of IL-2).
Endotoxin and interferon content of the partially purified supernatants
The limit of detection of the endotoxin standard with the LAL was 0.2 ng. By comparison with the standard endotoxin preparation in the kit, the IL-2 preparations had <2 ng/ml of endotoxin.
The IFN levels were <2.5uml-' in the injected preparations.
Clearance of IL-2 from the circulation After i.v. injection of IL-2, blood samples were taken at regular intervals. Serum from these samples were assayed for IL-2 activity as described.
The results in Figures 2 and 3 indicate an exponential clearance of IL-2 from the circulation over 1 h. A plot of the logarithm of the counts against time revealed that clearance of half the IL-2 activity from the circulation (Ti) took 22.5 min on both occasions in Patient 1. The equivalent Ti times in Patient 2 were 20 and 25 min respectively. A doseresponse curve for the infused IL-2 in a 30% dilution of the patient's pre-treatment serum was constructed as described to determine the units of IL-2 activity in the serum of the 2 recipients. The initial uml-1 obtained in the serum related to the dose given in that particular patient e.g. as shown in Figure 2 , in Patient 1 injection of 14,000 units gave an initial level of 3 uml-1 whereas 5,000 units gave an initial level of luml-'. In Patient 2 the injection of 17,000 and 67,000 units gave initial The levels of IL-2 obtained with a given dose of IL-2 varied between the 2 patients e.g. in Patient 1 a dose of 14,000 u gave -3 u ml-1 in the circulation whereas a dose of 17,000 u in Patient 2 gave 1 u ml-'. The Hb.1 11.9 13.0 11.6 11.4 11.5 11.2 11.0 11.0 11.0 10.6 10.6 10.6 10.1 10.7 WBC2 7.1 14.7 7.6 5.6 6.8 Hb. 12.9 13.3 12.2 12.8 13.2 13.8 13.6 13.4 12.3 12.6 11.9 12.6 13.5 14.2 14.0 13.3 13.5 13.0 13.0 WBC 9.6 20.9 11.6 8.1 9.4 9.3 8.5 12.2 23.5 32.6 11.9 8.7 10.1 10.4 12.6 10.6 11.5 8.0 8.4 Neut.
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Clinical observations
The following changes were observed clinically after i.v. injection of the IL-2 containing supernatants.
Rigors developed 10-15 min following injection and lasted for f-I h. This was followed by pyrexia at 38-39°C lasting from 2-6 h. The duration of the pyrexia was related to the number of IL-2 units injected. After 5,000 units the pyrexia lasted for 2 h and after 67,000 units for 6 h. Tachycardia of 100-120 was noted during the pyrexia and a transient drop of blood pressure of 5-15 mmHg diastolic occurred at the beginning of the pyrexia. The first patient developed nausea and vomiting 15 min after the second injection of 5,000 units. The second patient developed transient nausea 10-15min after the second injection of 67,000 units. Patient 1 was ambulant and attended for treatment as an outpatient. Patient 2 was an inpatient for stabilization of anti-coagulant therapy (given for a deep calf vein thrombosis which developed after his last surgical treatment) and for treatment of an ulcer over the lateral aspect of his left ankle. No clinically apparent adverse effects were noted in the days subsequent to the injections.
Immunoglobulin levels No significant change in immunoglobulins A, G or M levels were detected in serum samples from the 2 patients taken at weekly intervals over the study period (8-10 weeks).
Auto-antibodies Auto-antibodies to red blood cells, anti-nuclear factors, parietal cells, smooth muscle cells, thyroid tissue and mitochondria were not detected in pre-treatment serum samples or in samples taken 3 weeks after each treatment.
Rheumatoid factor was detected by the latex agglutination test both before and after treatment in Patient 2.
Cortisol levels An increase in cortisol levels were observed within 2h of the injections. The degree of the rise appeared related to the dose of IL-2 given. In Patient 2 after injection of 17,000 units peak cortisol levels of 720nM/l were seen at 4h. After 67,000 units peak levels of 1780nM/l were seen at 4 h. Pre-injection values were 280 and 270 nM/l respectively. The levels had returned to within the normal range 20 h after the injections (270 and 415 nM/l respectively. Normal range 280-830 nM/l).
Liver enzymes and blood glucose levels No significant change in the enzyme alkaline phosphatase, lactic dehydrogenase, glutamyl pyruvate, glutamyl oxalacetic and y-glutamyl transaminases were recorded at 1, 4 and 24h after the IL-2 injection. The serum glucose level in Patient 1 before and at 1, 4 and 24 h after injection of 14,000 units was 4.4, 3.3, 6.5 and 5.1 mMl-' respectively. (Normal venous fasting levels 3.9-6.1mMl-1). In Patient 2 levels of blood glucose before and at 1, 4 and 24 h after injection of 67,000 units was 5.3, 3.3, 5.3 and 5.8 respectively.
Effect of IL-2 on the coagulation system Patient 2 was on anti-coagulants and was not studied. At 45min after injection of 14,000 units in Patient 1 there was significant prolongation of the thrombin time from 14 to 30 sec and of the partial thromboplastin time with kaolin (PTTK) of 27 to 35 sec. These had returned to normal by 4 h. Moderate levels of fibrinogen degradation products (FDPs) were detected at 45min (40-80 ng ml -1) and fibrinogen levels were also low 45 min after the injections (15 mgml -') (Normal range, 200-400mg/ml). The latter had returned to normal by 4 h but 10-40 ng ml of FDPs were still present at this time.
IFN levels in serum following administration of IL-2 containing supernatants No significant levels of IFN (<1 unit/ml) were detected in serum samples taken at 1 and 4 h or at the daily intervals shown in 
Discussion
The dose of IL-2 given to the subjects in this study was selected so that an initial level of at least 2 u/ml in plasma would be obtained as this was the level used in vitro for induction of cytotoxic T cell activity (Hersey et al., 1981) . Based on an expected plasma volume of -4% of body weight and assuming no destruction or absorption of the IL-2 it would be expected that 14,000 u in Patient 1 would give an initial value of 7.3 u ml' (calculated plasma volume 1.921) and 17,000 u in Patient 2 an initial value of 5.8 u ml-1 (calculated plasma volume 2.921). Observed values were approximately 3 u/ml and 1 u/ml respectively. Similarly on the assumption that IL-2 equilibrated in total extracellular fluid (TEF) and that this was 19% of body weight it would be expected that the final level in Patient 1 would be 1.5u.ml-1 (calculated TEF=9.121) and 1.22u.ml in Patient 2 (calculated TEF=13.871). In fact zero levels were seen at 1 h. [Equivalent values for the second injection in both patients were Patient 1, expected initial 2.6 u ml' (observed approximately 1.25u/ml, Patient 2 expected initial 23 u/ml-1, observed approximately 6 u ml-')].
The discrepancy between the expected and observed IL-2 values in the circulation may be the result of several factors. One possibility is the IL-2 may be inactivated by factors in serum as reported to occur in mice (Wagner et al., 1980a) . Similar inactivation of IL-2 by human serum was not detected in the present studies. The mitogenic activity of IL-2 on activated T cells in vitro was only inhibited by high concentrations of fresh human serum and the induction of cytotoxic cells in vitro by IL-2 in autologous serum was comparable or only moderately reduced compared to that in FCS. We cannot exclude that factors inhibiting mitogenesis may have been released into the serum in vivo following IL-2 administration and that these may have influenced the clearance rates by their effect on the bioassay used in the study.
A second explanation for loss of IL-2 activity is that it was absorbed by activated T cells in vivo as shown to occur in vitro. (Smith et al., 1979; Watson & Mochizuki, 1980) . At high cell concentrations in vitro 70% of IL-2 activity was found to be absorbed in 30min (Smith et al., 1979) which is comparable to the clearance rate from the patient's serum found in the present study. Absorption of IL-2 by activated lymphocytes may explain why different levels of IL-2 were seen in the 2 patients for a given dose of IL-2. Patient 1 had a lower lymphocyte count than Patient 2 and hence less absorption of IL-2 and relatively higher serum levels of IL-2 may have occurred.
The latter explanation was supported by evidence of increased division of cells in the circulation after injection of the IL-2 containing preparations. This was consistent with absorption to and activation of cells in the circulation which expressed IL-2 receptors. Recent studies suggest the latter cells are activated into the G1 phase of the cell cycle by interaction with antigen but require IL-2 for subsequent cell division (Kristensen et al., 1982) . A number of clinical and biochemical effects were observed in the recipients of the IL-2 containing preparations which may have reflected the activity of contaminating monokines and lymphokines in the preparation, e.g. pyrexia may have resulted from interleukin I (IL-1) in the supernatants as the latter is believed to be synonymous with endogenous pyrogen (Murphy et al., 1980) . Similarly the transient hypoglycaemia and increase in FDPs may indicate the activity of such factors as glucocorticoid antagonizing factor (Moore et al., 1978) and thromboplastins (Geczy & Hopper, 1981) released from monocytes in the blood leukocyte preparations during IL-2 production. The increased platelet count, haemoglobin and metamyelocytes noted at 7 days may indicate the presence of colony stimulating factors in the preparations.
Elevation of glucocorticoids in the circulation was previously noted after injection of lymphokine preparations in rodents (Besedovsky et al., 1981) and may have been responsible in part for the neutrophilia and lymphocytopenia noted hours after the injections. Both the latter are well known systemic effects of corticosteroids. The systemic effects noted in these studies were similar to those reported after administration of a lymphokine preparation (Dumonde et al., 1982) and recombinant IFN except that neutropenia rather than neutrophilia was noted after the latter (Gutterman et al., 1982) . IFN was not detected in the IL-2 containing supernatants in the present study and it seems likely that the side effects common to these procedures are in part due to a stress response.
These results highlight the need for administration of purified preparations of IL-2 to allow the effects of IL-2 in vivo to be clearly defined. The present study, however, provides some encouragement that systemic administration of IL-2 may be a feasible approach for the activation of T cells in vivo. Such an approach would be technically much simpler than injection of cytotoxic T cells grown in vitro in the presence of IL-2 as described by previous authors (Mills et al., 1980; Warren et al., 1979; Gillis & Watson, 1981) and may allow activation of lymphocytes at the site of tumour growth. Although the half-life of 20-25min for IL-2 in the circulation appears relatively short this does not appear to be due to inactivation by serum factors. If subsequent studies confirm that clearance is at least in part due to absorption to activated T cells this may be sufficient to trigger these cells into cytotoxic activity despite the subsequent absence of detectable IL-2 in the circulation. Further studies with purified IL-2 preparations are required to answer these questions.
